申请人:Glaxo Group Limited
公开号:EP2206710A1
公开(公告)日:2010-07-14
The invention relates to compounds of formula (I)
wherein
one of R5 and R6 is hydrogen or R2 and the other is (a)
processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
本发明涉及式 (I) 的化合物
其中
R5 和 R6 中的一个是氢或 R2,另一个是 (a)
它们的制备工艺、含有它们的药物组合物以及它们在治疗通过 S1P1 受体介导的病症或紊乱中的用途。